We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Specialized White Blood Cells Prove Biomarkers for Diabetes Progression

By LabMedica International staff writers
Posted on 26 Aug 2019
Researchers have found that a specialized class of circulating white blood cells (CXCR5−PD-1hi Tph cells) are associated with progression for autoantibody positivity to clinical type I diabetes and have the potential to serve as biomarkers to monitor progression of this disease.

Type I diabetes is preceded by a period of asymptomatic autoimmunity characterized by positivity for pancreatic islet autoantibodies. More...
Therefore, T helper cell responses that induce B-cell activation are likely to play a critical role in the disease process.

To better understand the role of B-cell activation in type I diabetes, investigators at the University of Eastern Finland (Kuopio, Finland) aimed to evaluate the role of a recently described subset, C-X-C motif chemokine receptor type 5-negative, programmed cell death protein 1-positive (CXCR5−PD-1hi) peripheral T helper (Tph) cells, in human type I diabetes. C-X-C chemokine receptor type 5 (CXC-R5) is a G protein-coupled seven transmembrane receptor for chemokine CXCL13 (also known as BLC) and belongs to the CXC chemokine receptor family. It enables T-cells to migrate to lymph node B- cell zones.

Previous studies had found that the appearance of autoantibodies before clinical diabetes was caused by follicular helper T-cell activation of B-cells against proteins in the pancreatic islets. Peripheral helper T-cells (Tph) resemble follicular helper T-cells, but they express receptors that enable them to migrate to inflamed tissues.

For the current study, the investigators utilized samples from the Finnish DIPP (Type I Diabetes Prediction and Prevention) study in which the development of type I diabetes was followed from birth in children with genetic risk for the disease.

The frequencies of circulating CXCR5−PD-1hi T cells were analyzed by multicolor flow cytometry in a cohort of 44 children with newly diagnosed type I diabetes, 40 autoantibody-positive (AAb+) at-risk children, and 84 autoantibody-negative healthy control children. The findings were subsequently replicated in a separate cohort of 15 children with newly diagnosed type I diabetes and 15 healthy control children.

Results revealed that the frequency of circulating Tph cells was increased in children with newly diagnosed type I diabetes, especially in those who were positive for multiple autoantibodies. Importantly, circulating Tph cells were also increased in autoantibody-positive at-risk children who later progressed to type I diabetes.

"Based on our results, it is possible that peripheral helper T-cells may have a role in the development of type I diabetes. This information could be employed in the development of better methods to predict type I diabetes risk and new immunotherapies for the disease. However, more studies need to be conducted to verify our results and to further characterize the functionality of peripheral helper T- cells," said first author Ilse Ekman, a doctoral research student at the University of Eastern Finland.

The study was published in the September 2019 issue of the journal Diabetologia.

Related Links:
University of Eastern Finland


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Portable POCT Blood Gas Analyzer
BD100
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.